There is a “strong correlation” between obesity and the risk of dying from prostate cancer, a study has revealed. The US National Cancer Institute study examined the incidence and outcomes of prostate cancer in 287,760 men aged between 50 and 71.
UCLA researchers report that for patients hospitalized with acute heart failure, a higher body mass index (BMI) was associated with a substantially lower in-hospital mortality rate. The finding offers more insight into an observed phenomenon in chronic heart failure called the “obesity paradox.”
University of Pittsburgh investigators have successfully prevented the onset of type 1 diabetes in mice prone to developing the disease using an antibody against a receptor on the surface of immune T-cells. According to the investigators, these findings, which are being published in the January issue of the journal Diabetes, have significant implications for the prevention of type 1 diabetes.
Nutrition 21, Inc., today announced the results of a recent placebo controlled, double-blind, randomized, single center study that demonstrated that Diachrome, a patented combination of chromium picolinate and biotin, safely improves blood glucose levels and cholesterol metabolism in people with type 2 diabetes.
Results from the NHLBI Growth and Health Study of more than 2,300 girls suggest that girls as young as age 9 who are overweight are at increased risk for short-term and long-term problems that increase the chances of developing cardiovascular disease. Those who were overweight were more likely to have elevated blood pressure and cholesterol levels compared to girls who were not overweight. The study also provides insight into differences between African-American and Caucasian girls.
A new study finds that obesity increases the risk of death from prostate cancer, even though it does not increase the overall risk a man will be diagnosed with the disease. The study reveals that higher body mass index (BMI) and weight gain in adulthood correlated strongly with increased risk of death from prostate cancer.
Dogs are usually indulged in eating biscuits, and it causes obesity in them. Now dogs have slimming drug Slentrol, manufactured by Pfizer, to control obesity. The Food and Drug Administration (FDA) today is announcing the approval of Slentrol (dirlotapide), a prescription drug for the management of obesity in dogs.
The Food and Drug Administration (FDA) today is announcing the approval of Slentrol (dirlotapide), a prescription drug for the management of obesity in dogs. Slentrol reduces appetite and fat absorption to produce weight loss. A veterinarian will determine whether the dog should be treated, based on the dog’s weight and general health.
While millions of Americans place fitness as one of their top New Year’s resolutions to improve shape, muscle tone and overall appearance, cancer survivors have another priority — life.
If playing video games makes kids less active — and contributes to obesity — why not create more video games that require activity? That’s the question prompted by a Mayo Clinic research study published in the current issue of the medical journal Pediatrics.